JPS5840558B2 - ダウノマイシンユウドウタイノセイホウ - Google Patents
ダウノマイシンユウドウタイノセイホウInfo
- Publication number
- JPS5840558B2 JPS5840558B2 JP50153214A JP15321475A JPS5840558B2 JP S5840558 B2 JPS5840558 B2 JP S5840558B2 JP 50153214 A JP50153214 A JP 50153214A JP 15321475 A JP15321475 A JP 15321475A JP S5840558 B2 JPS5840558 B2 JP S5840558B2
- Authority
- JP
- Japan
- Prior art keywords
- daunomycin
- lower alkyl
- represent
- equivalent
- monohydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 title claims description 14
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 title description 10
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 title description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- 208000006268 Sarcoma 180 Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 3
- 239000002026 chloroform extract Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- WFCSWCVEJLETKA-UHFFFAOYSA-N 2-piperazin-1-ylethanol Chemical compound OCCN1CCNCC1 WFCSWCVEJLETKA-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101001031502 Mus musculus Histone H3.3C Proteins 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- TXFLGZOGNOOEFZ-UHFFFAOYSA-N bis(2-chloroethyl)amine Chemical compound ClCCNCCCl TXFLGZOGNOOEFZ-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- UDGSVBYJWHOHNN-UHFFFAOYSA-N n',n'-diethylethane-1,2-diamine Chemical compound CCN(CC)CCN UDGSVBYJWHOHNN-UHFFFAOYSA-N 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- -1 piperidino, pyrrolidino, morpholino, piperazino Chemical group 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB5579674A GB1469430A (en) | 1974-12-24 | 1974-12-24 | Daunomycin derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS51125268A JPS51125268A (en) | 1976-11-01 |
| JPS5840558B2 true JPS5840558B2 (ja) | 1983-09-06 |
Family
ID=10474914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP50153214A Expired JPS5840558B2 (ja) | 1974-12-24 | 1975-12-22 | ダウノマイシンユウドウタイノセイホウ |
Country Status (7)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES444380A1 (es) * | 1976-01-16 | 1977-06-16 | Gosalvez Mario | Un procedimiento para preparar derivados metalicos antraci- clinicos. |
| GB1518390A (en) * | 1976-03-30 | 1978-07-19 | Farmaceutici Italia | Doxorubicin thioesters |
| RU977462C (ru) | 1980-03-24 | 1995-06-27 | Отделение Института химической физики АН СССР | 13-(1-оксил-2,2,6,6-тетраметилпиперилиденил-4)гидразон рубомицина хлоргидрат с парамагнитным центром, проявляющий противоопухолевую активность, и способ его получения |
| GB9416007D0 (en) * | 1994-08-08 | 1994-09-28 | Erba Carlo Spa | Anthracyclinone derivatives |
| US10907145B2 (en) * | 2017-03-08 | 2021-02-02 | Arizona Board Of Regents On Behalf Of Arizona State University | Chemotherapeutic drug-conjugated resins and their preferential binding of methylated DNA |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3133912A (en) * | 1957-03-14 | 1964-05-19 | Benckiser Gmbh Joh A | Reaction product of amino carbohy-drates with therapeutically effective amino compounds |
| US3037015A (en) * | 1958-07-19 | 1962-05-29 | Benckiser Gmbh Joh A | Therapeutically valuable compounds and process of producing same |
| US3957755A (en) * | 1967-10-18 | 1976-05-18 | Rhone-Poulenc S.A. | Naphthacene derivatives |
| US3803124A (en) * | 1968-04-12 | 1974-04-09 | Farmaceutici It Soc | Process for the preparation of adriamycin and adriamycinone and adriamycin derivatives |
-
1974
- 1974-12-24 GB GB5579674A patent/GB1469430A/en not_active Expired
-
1975
- 1975-12-03 US US05/637,170 patent/US4024224A/en not_active Expired - Lifetime
- 1975-12-19 DE DE2557537A patent/DE2557537C3/de not_active Expired
- 1975-12-22 FR FR7539329A patent/FR2295756A1/fr active Granted
- 1975-12-22 HU HU75FA984A patent/HU173853B/hu not_active IP Right Cessation
- 1975-12-22 JP JP50153214A patent/JPS5840558B2/ja not_active Expired
- 1975-12-23 CH CH1672375A patent/CH602784A5/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CH602784A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1978-08-15 |
| DE2557537B2 (de) | 1979-02-15 |
| FR2295756A1 (fr) | 1976-07-23 |
| DE2557537C3 (de) | 1979-10-11 |
| FR2295756B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1978-07-28 |
| GB1469430A (en) | 1977-04-06 |
| JPS51125268A (en) | 1976-11-01 |
| US4024224A (en) | 1977-05-17 |
| HU173853B (hu) | 1979-09-28 |
| DE2557537A1 (de) | 1976-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2439787C (en) | Nitrogen-based camptothecin derivatives | |
| WO1990004918A2 (en) | Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions | |
| JPS5840558B2 (ja) | ダウノマイシンユウドウタイノセイホウ | |
| WO1989007441A1 (en) | 6-amino-1,2-benzopyrone antitumorigenic agents and method | |
| PT1142885E (pt) | Derivados de 2-(n-cianoimino)tiazolidin-4-ona | |
| US4474814A (en) | Radiosensitizing nitrobenzoic acid amide derivatives | |
| NZ227149A (en) | (2-piperazinyl)-2-oxoethylene-substituted flavonoid derivatives and pharmaceutical compositions | |
| US4242348A (en) | Novel basic substituted-alkylidenamino-oxylalkyl-carboxylic-acid esters | |
| DK1617843T3 (en) | Colchicine derivatives | |
| CN108640965B (zh) | 2-取代-18β-甘草次酸衍生物及其应用 | |
| WO1981003658A1 (en) | Diphenylbutyl-1-acylpiperazines | |
| US4638009A (en) | Derivatives of 3-pyrrolidinopropiophenone and a process for preparation thereof | |
| US4935425A (en) | 4H-quinolizin-4-ones for treatment of diseases associated with immunoglobulin e-antibody formation | |
| EP0212558A2 (en) | A radiation sensitizer | |
| EP0767788A1 (en) | New brefeldin a derivatives and their utility in the treatment of cancer | |
| FI60863B (fi) | Foerfarande foer framstaellning av nya bentshydryloxialkylaminderivat med foerlaengd antihistamineffekt | |
| FI80440B (fi) | Analogifoerfarande foer framstaellning av terapeutiskt anvaendbara afidkolanderivat. | |
| US4044023A (en) | Novel basic substituted-alkylidenamino-oxylalkylcarboxylic-acid esters | |
| US2475852A (en) | Morpholinoalkanol esters | |
| US7214714B2 (en) | 20-hydroxyeicosatetraenoic acid production inhibitors | |
| JP2004505072A (ja) | 新規なクマリン誘導体及びそれらの塩類、それらの調製方法及び薬学分野におけるそれらの使用 | |
| US2806032A (en) | Diphenolic therapeutic compounds | |
| US4021560A (en) | 2-[(Dimethylamino)(3-pyridyl)methyl]cyclohexanol and related compounds | |
| JPS591279B2 (ja) | 新規ヘレブリゲニンアシル誘導体、その製法及び該誘導体を含有する陽性走心筋作用医薬 | |
| CS228143B2 (en) | Production of derivatives of 1-amino-2-propanol |